Plexin-B1 Clinical Trials 2026: New Alzheimer’s Treatments Target Astrocytes, Not Just Amyloid
Last updated: May 20, 2026
Quick answer: In 2026, Plexin‑B1–related clinical trials focus on blocking the SEMA4D signaling pathway to reduce neuroinflammation and restore astrocyte function. Treatments like pepinemab aim to protect brain metabolism and potentially slow disease progression, while experimental therapies such as CAR‑astrocytes are being explored to actively remove amyloid plaques.
 |
| New 2026 therapies aim to restore astrocyte function rather than simply removing amyloid plaques. |
The Shift in Alzheimer’s Treatment Strategy
By 2026, Alzheimer’s research has begun shifting away from a singular focus on removing amyloid plaques. Instead, scientists are exploring how to modify the behavior of brain support cells, particularly astrocytes and microglia.
This emerging model recognizes that neurodegeneration is not only about protein accumulation, but also about how the brain’s cellular environment responds to that buildup.
One of the most promising pathways under investigation is the SEMA4D–Plexin‑B1 signaling axis.
1. The SIGNAL‑AD Trial and Pepinemab
What Pepinemab Does
Pepinemab is a monoclonal antibody designed to block Semaphorin‑4D (SEMA4D), a signaling protein that interacts with Plexin‑B1 receptors on astrocytes. [1](https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Pepinemab_%28drug_in_development%29.pdf)
When SEMA4D binds to these receptors, astrocytes can shift from supportive functions into a more inflammatory state, disrupting normal brain homeostasis. [2](https://www.biospace.com/press-releases/vaccinex-to-report-promising-new-efficacy-data-for-signal-ad-phase-1b-2-trial-of-pepinemab-at-clinical-trials-on-alzheimers-disease-ctad-conference-on-october-31-2024)
Clinical Trial Findings
In early-stage SIGNAL‑AD trials:
- Pepinemab was well tolerated, with no major treatment-related adverse events reported
- Patients showed improved brain metabolic activity in regions affected early by Alzheimer’s disease
These metabolic improvements were measured using FDG‑PET imaging and suggest a potential stabilization of neuronal function. [3](https://drug-dev.com/vaccinex-reports-positive-data-for-signal-ad-phase-1b-2-trial-of-pepinemab-in-alzheimers-disease/)
While these trials were not powered to definitively prove cognitive improvement, they provide early evidence that targeting astrocyte activity may influence disease progression.
2. Understanding the Plexin‑B1 Pathway
The Plexin‑B1 receptor is one of the primary binding targets for SEMA4D signaling. [1](https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Pepinemab_%28drug_in_development%29.pdf)
When activated, this pathway:
- Alters astrocyte structure and function
- Promotes inflammatory signaling
- Can disrupt normal neuronal support processes
Blocking this interaction is therefore being explored as a strategy to:
- Reduce neuroinflammation
- Preserve metabolic brain function
- Maintain blood–brain barrier stability (being investigated)
3. The Emerging Concept: Managing Plaque, Not Just Removing It
Recent research suggests that how the brain handles amyloid plaques may be as important as whether they are removed.
Astrocytes and microglia work together to manage waste in the brain. When functioning properly, they can help contain toxic protein buildup and support clearance through the glymphatic system. [4](https://medicalxpress.com/news/2026-04-excessive-cholesterol-astrocytes-linked-cognitive.html)
Disruption in these systems may accelerate inflammation and cognitive decline.
4. CAR‑Astrocyte Therapy: A New Experimental Approach
One of the most innovative research directions in 2026 involves genetically engineered astrocytes.
How It Works
Scientists have adapted CAR (Chimeric Antigen Receptor) technology—originally used in cancer treatment—to reprogram astrocytes with the ability to recognize amyloid proteins.
These engineered cells:
- Target amyloid‑beta plaques directly
- Engulf and break down protein aggregates
- Support brain cleanup processes
Research Findings (Preclinical)
- Reduced amyloid levels in animal models by approximately half
- Prevented plaque formation when applied early
These findings are based on preclinical (animal) research and represent a promising but still experimental approach. [5](https://www.sciencedaily.com/releases/2026/03/260311004720.htm)
Who Might Benefit from These Therapies?
Emerging biomarker research suggests that these therapies may be most relevant for individuals showing:
- Elevated markers of astrocyte activation (such as GFAP)
- Early Alzheimer’s pathology or mild cognitive impairment
- Evidence of neuroinflammatory processes
Clinical validation of patient selection criteria is still ongoing.
Key Takeaways for 2026
- Alzheimer’s treatment is shifting from plaque removal to cellular function restoration
- Plexin‑B1 and SEMA4D are promising targets for reducing neuroinflammation
- Pepinemab shows early evidence of metabolic brain benefits in clinical trials
- CAR‑astrocyte therapies represent a future “living drug” approach but remain experimental
Frequently Asked Questions
What is Plexin‑B1?
Plexin‑B1 is a receptor involved in cellular signaling pathways that regulate astrocyte behavior and inflammation in the brain.
Is pepinemab approved for Alzheimer’s?
No. Pepinemab is still in clinical development and has not been approved as a treatment.
Are CAR‑astrocyte therapies available to patients?
No. These therapies are currently in preclinical or early research stages and are not yet available outside clinical trials.
Why are astrocytes important?
Astrocytes support neurons, regulate blood flow, and help clear metabolic waste in the brain.
Conclusion: A New Direction in Brain Medicine
The 2026 clinical landscape reflects a major shift in neuroscience—from targeting disease markers to retraining the brain’s cellular systems.
By focusing on astrocytes and inflammatory signaling pathways like Plexin‑B1, researchers are exploring a more integrated and potentially safer approach to slowing neurodegeneration.
If you’re new to blood-based biomarker testing, start with how p-tau217 and molecular subtyping are changing Alzheimer’s care.
Because neuroinflammation is closely tied to stress physiology, you may also find helpful how the brain’s perception system can shape stress and health outcomes.
For supportive lifestyle strategies, see daily walking for brain and vascular health.
While many of these treatments are still experimental, they represent a meaningful evolution in how we understand and potentially treat Alzheimer’s disease.
📚 Clinical Citations & Reference Materials
1.German Center for Neurodegenerative Diseases (DZNE). (2026). Mechanisms of Astrocyte-Mediated Plaque Compaction and the Reduction of Synaptic Halo Toxicity. Science Daily Review.
2.Washington University School of Medicine. (2026). Phase I Safety Profiles and Efficacy of Chimeric Antigen Receptor (CAR) Astrocyte Transfections in Early-Onset Amyloid Pathologies. Neuroscience News Reports.
3. Journal of Neuroinflammation. (2025). Pepinemab and SEMA4D Blockade: Restoring Vascular Integrity and Glymphatic Flux in the Precision Medicine Era. Nature Portfolio.
4. Core AI4AD Consortium Database. (2026). Utilizing Plasma GFAP and p-tau217 Threshold Layouts to Stratify Neuro-Inflammatory Patient Cohorts for Targeted Cellular Therapeutics.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Clinical trial therapies discussed are experimental and may not be available or appropriate for all patients. Always consult a qualified healthcare provider before making medical decisions.